Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$13.07 USD
-0.45 (-3.33%)
Updated Jun 11, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KYTX 13.07 -0.45(-3.33%)
Will KYTX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KYTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for KYTX
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
12 Health Care Stocks Moving In Monday's Pre-Market Session
J.P. Morgan Predicts up to 210% Gains for These 2 ‘Strong Buy’ Stocks
Buy Rating for Kyverna Therapeutics Based on KYV-101’s Clinical Progress and Financial Stability